Predictive Potential of Acido-Basic Properties, Solubility and Food on Bioequivalence Study Outcome: Analysis of 128 Studies

Predictive Potential of Acido-Basic Properties, Solubility and Food on Bioequivalence Study Outcome: Analysis of 128 Studies

Publication: Drugs in R&D
Software: GastroPlus®

Risk assessment related to bioequivalence study outcome is critical for effective planning from the early stage of drug product development.

Modeling time‐delayed concentration‐QT effects with ACT ‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a 1 receptor) antagonist

Modeling time‐delayed concentration‐QT effects with ACT ‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a 1 receptor) antagonist

Publication: Pharmacology Research & Perspectives

The novel oral complement factor 5a receptor 1 antagonist ACT- 1014- 6470 was well tolerated in single- and multiple- ascending dose studies, including 24 h Holter electro-cardiogram (ECG) recordings evaluating its cardiodynamics based on data from singledoses of 30– 200 mg and twice- daily (b.i.d.) dosing of 30– 120 mg for 4.5 days.

Gastroplus and HSPiP Oriented Predictive Parameters as the Basis of Valproic Acid Loaded Mucoadhesive Cationic Nanoemulsion Gel for Improved Nose-To-Brain Delivery to Control Convulsion in Human

Gastroplus and HSPiP Oriented Predictive Parameters as the Basis of Valproic Acid Loaded Mucoadhesive Cationic Nanoemulsion Gel for Improved Nose-To-Brain Delivery to Control Convulsion in Human

Publication: Preprints.org
Software: GastroPlus®

Oral and parenteral delivery of first-line anticonvulsant Valproic cid (VA) are associated with serious adverse effects, high hepatic metabolism, high clearance, and low bioavailability in brain.

Physiologically-Based Pharmacokinetic Modelling of Rivoceranib Parent and Metabolite to Project DDI Risk and Support Regulatory Decision-Making

Physiologically-Based Pharmacokinetic Modelling of Rivoceranib Parent and Metabolite to Project DDI Risk and Support Regulatory Decision-Making

Conference: DDI
Software: GastroPlus®
Division: PBPK

The PBPK model for rivoceranib, an anticancer drug acting as a tyrosine kinase inhibitor (TKI) that selectively targets vascular...

Using AI-driven Drug Design to Shorten Your Drug Development Process

Using AI-driven Drug Design to Shorten Your Drug Development Process

Software: ADMET Predictor®
Division: PBPK

In this webinar, Dr. Jeremy Jones, Principal Scientist, will discuss how artificial intelligence (AI) can be used in the drug discovery and development process to identify viable candidate molecules and shorten time to market.

Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs

Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs

Authors: Deb S, Hopefl R
Publication: Daru Jour Pharma Sci
Software: GastroPlus®

Chemotherapy-induced nausea and vomiting are commonly experienced side effects in breast cancer (BCa) patients.

Development of Biopredictive Dissolution Method for Extended-Release Desvenlafaxine Tablets

Development of Biopredictive Dissolution Method for Extended-Release Desvenlafaxine Tablets

Publication: Pharmaceutics
Software: GastroPlus®

This study aimed to develop a biopredictive dissolution method for desvenlafaxine ER tablets using design of experiments (DoE)...

A Combined In-Vitro and GastroPlus® Modeling to Study the Effect of Intestinal Precipitation on Cinnarizine Plasma Profile in a Fasted State

A Combined In-Vitro and GastroPlus® Modeling to Study the Effect of Intestinal Precipitation on Cinnarizine Plasma Profile in a Fasted State

Publication: AAPS PharmSciTech
Software: GastroPlus®

Poorly water-soluble weak base molecules such as cinnarizine often exhibit pH-dependent solubility within the gastrointestinal tract.

Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes

Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of a new integrated pulmonary software and services package.